Illumina, Inc. vs abrdn Physical Palladium Shares ETF — how do they compare? Illumina, Inc. trades at $278.17 (market cap $39.95B), while abrdn Physical Palladium Shares ETF trades at $20.77 (market cap $586.03M). The key difference: Illumina, Inc. is far larger — about 68.2× abrdn Physical Palladium Shares ETF's market cap, and Illumina, Inc. is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and abrdn Physical Palladium Shares ETF for 33 Days on average.
| ILMN | PALL | |
|---|---|---|
Market Cap | $39.95B | $586.03M |
Volume | 3,169,503 | 1,257,028 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $293.69 | $37.18 |
52-Week Low | $91.00 | $20.30 |
Typical Hold Time | 83 Days | 33 Days |
Enterprise Value | $41.31B | — |
Signals from Pluang's Aura AI — not financial advice
ILMN trades at $264.40, down 1.25% on the day, but remains near its recent 52-week high of $278.99 (Defense World, 2026-10-01). The stock has surged 94.9% year-to-date (Zacks Investment Research, 2026-09-24), supported by strong earnings beats in recent quarters and a bullish technical trend. Fundamentals show a significant turnaround, with 2025 net income reaching $850 million after prior losses, though valuation ratios like a P/E of 49.36 are elevated. The pending inclusion in the S&P 500 (PRNewsWire, 2026-09-04) adds a positive catalyst.
The outlook is positive, driven by sequencing growth, AI integration in genomics, and improved profitability. However, risks include high valuation sensitivity, cost volatility, and competitive pressures in the life sciences sector. Analyst consensus is bullish with a 54% buy rating, but the average price target of $241 suggests limited near-term upside from current levels.
PALL trades at $20.77, up 2.32% today, but technical indicators show a bearish trend with moving averages unanimously negative. The ETF faces fundamental data gaps in valuation and profitability metrics. Recent news highlights palladium's underperformance versus other precious metals, with some analysts seeing current price weakness as a buying opportunity given supply risks and industrial demand potential.
The outlook remains cautious with strong bearish technical signals offset by potential catch-up trade opportunities. Key risks include commodity price volatility and industrial demand fluctuations, while potential upside depends on palladium market dynamics reversing recent weakness.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →